Composition
- Active ingredients
- BISACODYL 5MG,N/A; POLYETHYLENE GLYCOL 3350 N/A,210GM; POTASSIUM CHLORIDE N/A,0.74GM; SODIUM BICARBONATE N/A,2.86GM; SODIUM CHLORIDE N/A,5.6GM
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- BISACODYL 5MG,N/A; POLYETHYLENE GLYCOL 3350 N/A,210GM; POTASSIUM CHLORIDE N/A,0.74GM; SODIUM BICARBONATE N/A,2.86GM; SODIUM CHLORIDE N/A,5.6GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · For solution, tablet, delayed releaseNDA021551-003 · Discontinued
- BISACODYL 5MG,N/A; POLYETHYLENE GLYCOL 3350 N/A,210GM; POTASSIUM CHLORIDE N/A,0.74GM; SODIUM BICARBONATE N/A,2.86GM; SODIUM CHLORIDE N/A,5.6GM · For solution, tablet, delayed releaseThis page
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application NDA021551.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Brand name
- Halflytely
- Active substance
- bisacodyl
- Route
- Oral
- Dosage form
- For solution, tablet, delayed release
- Applicant
- Braintree
- Status
- Discontinued
- FDA approval
- 10 May 2004
- Application
- NDA021551-002